Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "EMBARK Trial - Outcomes of Men With High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment"
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Neal Shore
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Neal Shore
Login to view comments.
Click here to Login